Last updated: November 2, 2026
Vaxchora is the only FDA-licensed oral cholera vaccine marketed in the United States. Its commercial value is driven by international travel, outbreak preparedness, humanitarian procurement, and public-health demand rather than routine vaccination. Bavarian Nordic acquired Vaxchora from Emergent BioSolutions as part of a broader travel-health portfolio transaction and now controls its commercial development.
Standalone Vaxchora revenue is not publicly disclosed. Bavarian Nordic reports the product within its Travel Health portfolio, which limits precise valuation and product-level growth analysis. The product has a defensible regulatory position but a narrow addressable market, limited routine-use recommendations, and demand that can fluctuate sharply with travel volumes and cholera outbreaks.
What is Vaxchora and how does it work?
Vaxchora is a live, attenuated oral vaccine containing the genetically modified Vibrio cholerae strain CVD 103-HgR. The vaccine is administered as a single oral dose and is approved in the United States for adults and children aged two years and older traveling to areas affected by cholera transmission.[1]
The vaccine is designed to reduce the risk of illness caused by V. cholerae serogroup O1. It does not provide protection against all causes of acute diarrhea and is not a substitute for food, water, and sanitation precautions.
| Attribute |
Vaxchora |
| Active vaccine |
Live attenuated Vibrio cholerae CVD 103-HgR |
| Route |
Oral |
| Dose |
Single dose |
| U.S. indication |
Travelers aged two years and older to cholera-affected areas |
| U.S. approval |
2016 |
| Pediatric expansion |
FDA expanded use to children aged two years and older in 2021 |
| Current commercial owner |
Bavarian Nordic |
| Primary market |
International travel and outbreak-risk populations |
| Product type |
Live oral bacterial vaccine |
Vaxchora’s single-dose oral format differentiates it from injectable vaccines and may support use in travel clinics, pharmacies, military settings, and emergency-response programs.
Who owns Vaxchora and what was the licensing history?
Vaxchora was originally developed by PaxVax. Emergent BioSolutions acquired PaxVax in 2018, obtaining Vaxchora and other travel-health assets. Bavarian Nordic later acquired Emergent’s travel-health business for approximately $270 million in a transaction that included Vaxchora, Vivotif, and rabies-vaccine rights.[2]
| Period |
Ownership or regulatory event |
| Before 2018 |
Vaxchora associated with PaxVax |
| 2018 |
Emergent acquired PaxVax |
| 2016 |
FDA approved Vaxchora for adults |
| 2021 |
FDA expanded indication to children aged two years and older |
| 2023 |
Bavarian Nordic acquired the travel-health portfolio from Emergent |
| Current |
Bavarian Nordic markets Vaxchora in the United States |
The transaction gave Bavarian Nordic an established commercial infrastructure in travel vaccines. It also added a product with a different demand profile from the company’s smallpox and mpox vaccine business.
What is the FDA regulatory status of Vaxchora?
Vaxchora is licensed by the FDA as a biologic vaccine. The current U.S. label covers adults and pediatric patients aged two years and older who are traveling to areas where cholera is actively transmitted.[1]
The vaccine is not recommended for routine vaccination of the general U.S. population. The Centers for Disease Control and Prevention recommends consideration of cholera vaccination for travelers at increased risk, while emphasizing that most travelers do not need the vaccine.[3]
The label creates several commercial constraints:
- Demand depends on travel to recognized cholera-risk areas.
- The vaccine is not a universal travel requirement.
- Travel-clinic utilization can fall during geopolitical disruptions, pandemics, or reduced international mobility.
- The product is not positioned as a routine childhood vaccine.
- Public-health demand can increase during outbreaks or humanitarian emergencies.
FDA approval does not guarantee broad reimbursement. Travel vaccines are frequently paid out of pocket, although employers, government programs, military organizations, and institutional buyers may purchase them under separate arrangements.
When does Vaxchora lose exclusivity?
Vaxchora received FDA approval in 2016. As a biologic licensed under the Public Health Service Act, it may receive 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, subject to the statutory framework and any applicable regulatory adjustments.[4]
On a straightforward approval-date calculation, the reference-product exclusivity period would extend to approximately 2028. That date should not be treated as a guaranteed generic or biosimilar launch date. FDA exclusivity, patent rights, manufacturing complexity, and product-specific approval requirements operate separately.
| Exclusivity element |
Vaxchora assessment |
| FDA approval |
2016 |
| Potential 12-year biologic exclusivity endpoint |
Approximately 2028 |
| Small-molecule generic pathway |
Not applicable |
| Expected competitive pathway |
Product-specific vaccine competition; biosimilar pathway is not an established near-term route |
| Practical market protection |
Regulatory know-how, live-organism manufacturing, brand, supply, and distribution |
Vaxchora is unlikely to face a conventional Hatch-Waxman generic launch. A competing oral live cholera vaccine would need its own development, manufacturing validation, clinical package, and regulatory approval.
What patents protect Vaxchora?
The commercial protection for Vaxchora is more complex than a typical small-molecule drug patent estate. The product is based on an attenuated bacterial strain and a live-biologic manufacturing process. Relevant protection may include strain construction, genetic modification, formulation, stabilization, fermentation, quality control, and methods of use.
Publicly available product materials do not provide a simple, current Orange Book-style list that captures the full Vaxchora protection position. Vaccine biologics also do not fit neatly into the small-molecule patent-listing model used for many FDA-approved drugs.
Does Vaxchora have Orange Book patents?
Vaxchora is not exposed to the same Orange Book framework as a conventional orally administered chemical drug. Its competitive position depends more heavily on:
- The FDA biologic license;
- Manufacturing process control;
- Proprietary cell banks and seed stocks;
- Strain and genetic-engineering know-how;
- Stability and formulation data;
- Trade secrets;
- Regulatory and commercial scale-up capability.
No major Vaxchora Paragraph IV challenge has become a central publicly reported market event. The absence of a reported Paragraph IV case is consistent with the product’s biologic and live-vaccine characteristics, where a conventional abbreviated generic pathway is not available.
What formulation patents protect Vaxchora?
The commercial formulation must preserve viability of the live attenuated organism through manufacturing, storage, transport, and administration. Formulation and stabilization know-how can therefore be commercially important even when broad composition patents are old, narrow, expired, or difficult to enforce.
The strongest practical barriers may be process-based rather than formulation-based. A competitor would need to produce a stable, consistent live vaccine at commercial scale and demonstrate acceptable safety, immunogenicity, and lot-to-lot quality.
How large is the Vaxchora market?
Vaxchora addresses a specialized market rather than the global routine-vaccine market. Its demand pools are:
- International travelers to cholera-risk regions.
- Military and government personnel.
- Humanitarian and disaster-response organizations.
- Residents or workers in outbreak settings.
- Travel clinics, hospitals, occupational-health providers, and specialty pharmacies.
The World Health Organization reports substantial global cholera activity, but the existence of outbreaks does not translate directly into Vaxchora sales. Cholera prevention programs often prioritize water, sanitation, hygiene, oral rehydration, case management, and mass vaccination campaigns using vaccines selected for public-health logistics and procurement economics.[5]
In the United States, Vaxchora benefits from limited direct competition in the oral cholera traveler segment. Its market is constrained by the CDC’s targeted-use approach and by the fact that most travelers do not require vaccination.
What is Vaxchora’s financial trajectory?
Bavarian Nordic does not separately disclose Vaxchora revenue, gross margin, unit volume, or operating profit. The product is reported within the company’s broader Travel Health business. As a result, company-level travel-health revenue cannot be attributed to Vaxchora without estimation.
The financial trajectory is best understood through four variables:
| Driver |
Effect on Vaxchora |
| International travel |
Supports clinic visits and traveler vaccination |
| Cholera outbreaks |
Creates episodic demand and public-health visibility |
| CDC guidance |
Limits routine or broad consumer uptake |
| Bavarian Nordic distribution |
Improves portfolio selling and channel access |
Bavarian Nordic’s acquisition strategy added Vaxchora to a portfolio that includes rabies and typhoid products. That portfolio structure can reduce customer-acquisition costs and improve access to travel clinics, pharmacies, government buyers, and distributors.[2]
The product’s revenue profile is likely seasonal. Travel vaccination typically rises before peak travel periods, while outbreak-driven orders may create short-term surges. The lack of standalone disclosure means investors should avoid treating all Travel Health growth as evidence of Vaxchora growth.
What are the main revenue risks?
The principal risks are market-size and utilization risks rather than immediate generic erosion.
- Most travelers do not receive cholera vaccination.
- International travel volumes can fall rapidly.
- Cholera vaccine demand depends on geography-specific recommendations.
- Public procurement may favor lower-cost oral cholera vaccines for mass campaigns.
- Live vaccines require specialized manufacturing and cold-chain management.
- Supply interruptions can affect travel-clinic confidence and purchasing patterns.
- The product has limited use outside cholera-risk settings.
What are the principal upside drivers?
Potential growth drivers include:
- Expanded travel after periods of suppressed international mobility;
- More frequent or geographically broader cholera outbreaks;
- Government and humanitarian stockpiling;
- Wider availability through pharmacies and telehealth-linked travel services;
- Pediatric use following the 2021 label expansion;
- Portfolio cross-selling with rabies and typhoid vaccines;
- Increased recognition of cholera risk among travelers and occupational groups.
How does Vaxchora compare with competing cholera vaccines?
Vaxchora is differentiated by its U.S. approval, single-dose regimen, and oral delivery. Internationally, it competes with other oral cholera vaccines, including Euvichol-Plus and Dukoral, although regulatory status, labeling, procurement channels, and target populations differ by country.
| Product |
Delivery |
Typical commercial positioning |
| Vaxchora |
Single-dose oral live vaccine |
U.S. travelers and selected risk groups |
| Dukoral |
Oral, multi-dose regimen |
International travelers and certain national markets |
| Euvichol-Plus |
Oral inactivated vaccine |
Public-health and mass-vaccination programs |
| Shanchol |
Oral inactivated vaccine |
International public-health procurement |
Vaxchora’s main commercial advantage is not broad global market share. It is its position in the U.S. travel-health channel. Its main competitive weakness is the narrow U.S. indication and lack of routine vaccination demand.
Which companies are challenging Vaxchora?
No public competitor has established a near-term U.S. biosimilar or generic launch comparable to a conventional pharmaceutical Paragraph IV challenge. Competition is more likely to arise from:
- Other cholera-vaccine manufacturers seeking U.S. or international approvals;
- Public-health suppliers competing for government tenders;
- Alternative vaccines used outside the United States;
- Non-vaccine prevention programs;
- Procurement substitution during outbreaks.
The most relevant competitive threat is not necessarily patent litigation. It is substitution by lower-cost vaccines in institutional or international markets.
What patent litigation and settlement agreements affect Vaxchora?
No major publicly reported Vaxchora patent settlement or Paragraph IV litigation has defined the product’s commercial outlook. The absence of such litigation reflects the product’s biologic status and the specialized development requirements for live oral vaccines.
A future challenger would face regulatory and manufacturing barriers even if it avoided or invalidated relevant patents. The practical launch timeline would depend on clinical development, FDA review, facility qualification, quality systems, and reliable supply.
What generic launch scenarios exist for Vaxchora?
Three scenarios are commercially plausible:
Scenario 1: No direct U.S. competitor before 2028
Bavarian Nordic retains the U.S. market with demand driven by travel, outbreaks, and institutional purchasing. This is the most straightforward scenario if no competing vaccine developer advances a U.S. program.
Scenario 2: Product-specific vaccine competition
A competing oral cholera vaccine obtains approval or enters through a public-health procurement channel. Price pressure would be strongest in institutional accounts and weaker in branded travel clinics.
Scenario 3: Demand substitution without a U.S. generic
International buyers use alternative oral cholera vaccines, while Vaxchora remains focused on the U.S. traveler market. This could limit global expansion without directly reducing U.S. exclusivity.
How strong is the Vaxchora commercial and IP estate?
Vaxchora has a moderate commercial moat and a stronger operational moat than patent moat.
Its strengths are FDA approval, limited U.S. competition, a single-dose oral regimen, established travel-health channels, and specialized live-vaccine manufacturing. Its weaknesses are the narrow indication, episodic demand, limited routine use, lack of standalone revenue disclosure, and exposure to alternative international vaccines.
The product is strategically useful within Bavarian Nordic’s Travel Health portfolio, but it is unlikely to be valued like a mass-market pediatric or adult routine vaccine without a major change in recommendations or procurement demand.
Key Takeaways
- Vaxchora is an FDA-licensed live oral cholera vaccine for travelers aged two years and older.
- Bavarian Nordic owns and markets the product after acquiring Emergent’s travel-health portfolio.
- Standalone Vaxchora revenue is not publicly disclosed.
- Financial performance depends on travel activity, cholera outbreaks, public-health orders, and travel-clinic utilization.
- The product may have biologic exclusivity through approximately 2028, but that date does not imply an automatic generic launch.
- Vaxchora is not exposed to a conventional small-molecule Paragraph IV pathway.
- The strongest barriers are manufacturing, regulatory, quality, and distribution capabilities.
- The main competitive threat is substitution by other oral cholera vaccines in international or institutional markets.
- The U.S. market remains commercially attractive because Vaxchora has limited direct competition, but its total addressable population is narrow.
FAQs About Vaxchora Market and Exclusivity
Is Vaxchora a routine vaccine?
No. Vaxchora is intended for selected travelers and other people at increased risk of exposure to cholera. It is not part of routine U.S. childhood or adult vaccination schedules.
Can a generic company make Vaxchora?
A conventional generic pathway is unlikely. A competitor would generally need to develop and obtain approval for its own cholera vaccine, supported by manufacturing, clinical, safety, and quality data.
Does Vaxchora have biosimilar risk?
Near-term biosimilar risk appears limited. Vaccine competition is more likely to come from independently developed oral cholera vaccines than from a standard biosimilar filing.
Who manufactures Vaxchora?
Vaxchora is marketed by Bavarian Nordic, which acquired the relevant travel-health assets from Emergent BioSolutions. Manufacturing and distribution arrangements can vary by market and are subject to the product’s biologic license and quality requirements.
Is Vaxchora commercially exposed to cholera outbreaks?
Yes. Outbreaks can increase awareness, institutional orders, and travel-clinic demand. The effect is uneven because public-health agencies may select different vaccines based on price, supply, formulation, and campaign logistics.
References
- U.S. Food and Drug Administration. (2021). Vaxchora prescribing information.
- Bavarian Nordic. (2023). Bavarian Nordic completes acquisition of Emergent BioSolutions’ travel health business.
- Centers for Disease Control and Prevention. (2024). Cholera vaccination: Travelers’ health.
- U.S. Food and Drug Administration. (2024). Licensure of biological products and reference product exclusivity under the Public Health Service Act.
- World Health Organization. (2024). Cholera vaccines: Position paper and global cholera control guidance.
